The current role of targeted therapies to induce radioiodine uptake in thyroid cancer
- 1 June 2014
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 40 (5), 665-674
- https://doi.org/10.1016/j.ctrv.2014.01.002
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Screening of selective histone deacetylase inhibitors by proteochemometric modelingBMC Bioinformatics, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerNew England Journal of Medicine, 2012
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationJCI Insight, 2011
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging CorrelationClinical Cancer Research, 2010
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced CancersClinical Cancer Research, 2008
- Induction of sodium iodide symporter gene and molecular characterisation of HNF3β/FoxA2, TTF-1 and C/EBPβ in thyroid carcinoma cellsBritish Journal of Cancer, 2008
- Reinduction of Cell Differentiation and 131I Uptake in a Poorly Differentiated Thyroid Tumor in Response to the Reverse Transcriptase (RT) Inhibitor NevirapineCancer Biotherapy & Radiopharmaceuticals, 2007
- Targeting BRAF in thyroid cancerBritish Journal of Cancer, 2006